{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:33:32Z","timestamp":1792164812817,"version":"4.4.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1097\/wnf.0b013e31811510ed","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T14:07:54Z","timestamp":1236262074000},"page":"134-140","source":"Crossref","is-referenced-by-count":11,"title":["Catechol-O-methyltransferase Inhibition Improves Levodopa-Associated Strength Increase in Patients With Parkinson Disease"],"prefix":"10.1097","volume":"31","author":[{"given":"Thomas","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Kolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lema","family":"Ander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Woitalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Muhlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210203","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/mds.10710","article-title":"Grip force abnormalities in de novo Parkinson's disease.","volume":"19","author":"Fellows","year":"2004","journal-title":"Mov Disord"},{"key":"R2-2-20210203","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1017\/S0317167100001062","article-title":"Correlation between tapping and inserting of pegs in Parkinson's disease.","volume":"27","author":"Muller","year":"2000","journal-title":"Can J Neurol Sci"},{"issue":"pt 9","key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/brain\/121.9.1771","article-title":"Precision grip and Parkinson's disease.","volume":"121","author":"Fellows","year":"1998","journal-title":"Brain"},{"key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/exnr.1997.6479","article-title":"Anticipatory control of manipulative forces in Parkinson's disease.","volume":"145","author":"Gordon","year":"1997","journal-title":"Exp Neurol"},{"issue":"pt 3","key":"R5-2-20210203","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/brain\/120.3.401","article-title":"Does parkinsonian action tremor contribute to muscle weakness in Parkinson's disease?","volume":"120","author":"Brown","year":"1997","journal-title":"Brain"},{"key":"R6-2-20210203","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/brain\/awf084","article-title":"Force overflow and levodopa-induced dyskinesias in Parkinson's disease.","volume":"125","author":"Wenzelburger","year":"2002","journal-title":"Brain"},{"key":"R7-2-20210203","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/mds.10505","article-title":"Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.","volume":"18","author":"Lou","year":"2003","journal-title":"Mov Disord"},{"key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1212\/WNL.51.6.1583","article-title":"Enhanced fatigue during motor performance in patients with Parkinson's disease.","volume":"51","author":"Ziv","year":"1998","journal-title":"Neurology"},{"key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/1097-4598(200009)23:9<1393::AID-MUS10>3.0.CO;2-O","article-title":"Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies.","volume":"23","author":"Merkies","year":"2000","journal-title":"Muscle Nerve"},{"key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/mds.10591","article-title":"Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program.","volume":"18","author":"Goetz","year":"2003","journal-title":"Mov Disord"},{"key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000117399","article-title":"The CR First Study Group. Comparison of immediate-release and controlled release carbidopa\/levodopa in Parkinson's disease. A multicenter 5-year study.","volume":"37","author":"Block","year":"1997","journal-title":"Eur Neurol"},{"key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.53.5.1012","article-title":"Carbidopa\/Levodopa Study Group. Immediate-release and controlled-release carbidopa\/levodopa in PD: a 5-year randomized multicenter study.","volume":"53","author":"Koller","year":"1999","journal-title":"Neurology"},{"key":"R13-2-20210203","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1212\/WNL.44.5.913","article-title":"Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.","volume":"44","author":"Nutt","year":"1994","journal-title":"Neurology"},{"key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1468-1331.1995.tb00137.x","article-title":"Entacapone in combination with standard or controlled-release levodopa carbidopa-a clinical and pharmacokinetic study in patients with Parkinson's disease.","volume":"2","author":"Kaakkola","year":"1995","journal-title":"Eur J Neurol"},{"key":"R15-2-20210203","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.68.5.589","article-title":"The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.","volume":"68","author":"Piccini","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R16-2-20210203","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R17-2-20210203","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00702-006-0442-5","article-title":"Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa\/carbidopa with and without entacapone in patients with Parkinson's disease.","volume":"113","author":"Muller","year":"2006","journal-title":"J Neural Transm"},{"key":"R18-2-20210203","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00002826-199304000-00007","article-title":"The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.","volume":"16","author":"Keranen","year":"1993","journal-title":"Clin Neuropharmacol"},{"key":"R19-2-20210203","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00003088-200140050-00005","article-title":"Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.","volume":"40","author":"Baas","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"R20-2-20210203","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/phrs.1997.0145","article-title":"Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association.","volume":"35","author":"Benetello","year":"1997","journal-title":"Pharmacol Res"},{"key":"R21-2-20210203","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF02251244","article-title":"Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats.","volume":"2","author":"Mannisto","year":"1990","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"R22-2-20210203","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ana.410310611","article-title":"3-O-methyldopa administration does not alter fluorodopa transport into the brain.","volume":"31","author":"Guttman","year":"1992","journal-title":"Ann Neurol"},{"key":"R23-2-20210203","first-page":"R409","article-title":"Metabolic regulation via intracellular pH.","volume":"246","author":"Busa","year":"1984","journal-title":"Am J Physiol"},{"key":"R24-2-20210203","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1152\/jappl.1988.65.2.509","article-title":"Regulation of lactic acid production during exercise.","volume":"65","author":"Katz","year":"1988","journal-title":"J Appl Physiol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-200805000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:51:35Z","timestamp":1618278695000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200805000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e31811510ed","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}